匹多莫德颗粒治疗小儿反复呼吸道感染的临床效果分析
| 作者: |
1黄国华,
1卢双龙
1 上海市同济医院儿科，上海 200065 |
| 通讯: |
黄国华
Email: huangguohua1974@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2014.06.018 |
摘要
目的：分析匹多莫德颗粒治疗小儿反复呼吸道感染的临床效果。方法：选取2012年6月至2013年6 月在上海市同济医院收治的反复呼吸道感染患儿64例，随机分为常规治疗组，常规治疗+匹多莫德 组，比较两组患者治疗前后的症状表现情况、免疫水平及疗效。结果：常规治疗+匹多莫德组的总 有效率(90.6%)明显高于常规治疗组(62.5%)，差异具有统计学意义(P<0.05)。常规治疗+匹多莫德 组退热时间为(3.71±1.03) d，止咳时间为(4.28±2.83) d，肺部啰音消失时间为(4.96±2.16) d；常规 治疗组退热时间为(5.32±0.96) d，止咳时间为(8.77±2.47) d，肺部啰音消失时间为(6.21±1.98) d。 以上差异均有统计学意义(P<0.05)。疗程结束后，两组患者的IgG、IgA、IgM水平及CD4 +/CD8 +比 值均明显升高，且常规治疗+匹多莫德组的变化比常规治疗组更大，组间差异明显，具有统计学意 (P<0.05)。结论：匹多莫德颗粒在小儿反复呼吸道感染的治疗上具有明显优势，配合常规对症治疗 能够取得更好的临床效果。
关键词：
匹多莫德
小儿反复呼吸道感染
临床效果
免疫水平
症状表现
The clinical effects analysis of Pidotimod particle therapy in children with recurrent respiratory tract infections
CorrespondingAuthor: HUANG Guohua Email: huangguohua1974@163.com
DOI: 10.3978/j.issn.2095-6959.2014.06.018
Abstract
Objective: To analyze the treatment effects of Pidotimod particles clinical on children with recurrent respiratory tract infections. Methods: A total of 64 cases of repeated respiratory infection were selected from June 2012 to June 2013 admitted to hospital and randomly divided into conventional treatment group and conventional treatment + Pidotimod group. The symptoms, the immunity level and efficacy of two groups were compared before and after treatment. Results: The total efficiency of the conventional treatment + Pidotimod group (90.6%) was significantly higher than conventional treatment group (62.5%), the difference was statistically significant (P<0.05). Antifebrile time of conventional treatment + Pidotimod group was (3.71±1.03) d, cough time (4.28±2.83) d, pulmonary rales disappeared time (4.96±2.16) d; Antifebrile time of the conventional treatment group was (5.32±0.96) d, cough time (8.77±2.47) d, pulmonary rales disappeared time o (6.21±1.98) d. The differences of Antifebrile time, cough time and pulmonary rales disappeared time between two group were statistically significant (P<0.05). At the end of treatment, the level of IgG, IgA, IgM and CD4 +/CD8 + ratio of two group increased significantly, and the the increased change of the conventional treatment + Pidotimod group were greater than the conventional treatment group (P<0.05). Conclusion: Pidotimod particles have obvious advantages in the treatment of recurrent respiratory tract infections, and can achieve better clinical results with conventional symptomatic treatment.